Lillian Bussema

Helix predicts A-to-I RNA editing by ADARs with high accuracy using a structure-aware transformer model, enabling efficient gRNA design for therapeutic applications.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.